SCHEMBL23848043

SCHEMBL23848043

CC(C)(C)OC(=O)NCCNc1cccc(F)c1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 1/20 0.47
CDK2 P24941 1/20 0.46
BCHE P06276 1/20 0.46
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
NQO2 P16083 1/20 0.43
SCN9A Q15858 1/20 0.42
BRD4 O60885 1/20 0.42
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
IDO1 P14902 2/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
PIM1 P11309 1/20 0.39
PIM2 Q9P1W9 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
LATS1 O95835 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
SUV39H2 Q9H5I1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25470877 0.81 MALT1 (0.54) MALT1CDK2BCHEDDB1CRBN
SCHEMBL20974334 0.80 MALT1 (0.47) MALT1CDK2BCHEDDB1CRBN
SCHEMBL23835398 0.79 SMN1; SMN2 (0.42)
SCHEMBL12311297 0.79 BRD4 (0.49) MALT1BCHESCN9ABRD4IDO1
SCHEMBL30151772 0.79 SCN9A (0.59) NQO2SCN9AIDO1
SCHEMBL20974285 0.78 MALT1 (0.44) MALT1BCHEDDB1CRBNNQO2
SCHEMBL21710422 0.78 AAK1 (0.46) MALT1CDK2BCHEDDB1CRBN
SCHEMBL19950485 0.77 RIPK1 (0.45) NQO2SCN9AIDO1LMNAPOLB
SCHEMBL16011811 0.76 MALT1 (0.49) MALT1BCHEDDB1CRBNNQO2
SCHEMBL29655427 0.76 MALT1 (0.54) MALT1CDK2BCHEDDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121421-B1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2026-03-11 EP disclosed
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 US disclosed
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors NOVARTIS AG (CH) 2024-09-10 US disclosed
EP-4121421-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS Novartis AG (CH) 2023-01-25 EP disclosed
US-20210299100-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2021-09-30 US disclosed
WO-2021186324-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors YAP1, TEAD3, TEAD2 MALT1 4276/4885CDK2 1248/4885BCHE 3446/4885
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 MALT1 4276/4885CDK2 1248/4885BCHE 3446/4885
US-20210299100-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 MALT1 4157/4885CDK2 1223/4885BCHE 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.